Minerva Neurosciences Inc Market Cap ($109.48 Million)
Market Cap & Net Worth: Minerva Neurosciences Inc (NERV)
Minerva Neurosciences Inc market cap. Minerva Neurosciences Inc (NASDAQ:NERV) has a market capitalization of $109.48 Million ($109.48 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18640 globally and #4343 in its home market, demonstrating a 6.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Minerva Neurosciences Inc's stock price $2.35 by its total outstanding shares 46588709 (46.59 Million). Also see NERV cash generation efficiency for how efficiently the company converts equity into cash flow.
Minerva Neurosciences Inc Market Cap History (2015–2026)
Minerva Neurosciences Inc market cap history from 2015 to 2026. Data shows change from $2.26 Billion to $109.48 Million (-23.01% CAGR). Check Minerva Neurosciences Inc stock price for real-time trading data and today's change.
Index Memberships
Minerva Neurosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #509 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1790 of 3165 |
Weight: Minerva Neurosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Minerva Neurosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Minerva Neurosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NERV net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
21.18x
Minerva Neurosciences Inc's market cap is 21.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
449.33x
Minerva Neurosciences Inc's market cap is 449.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.65 Billion | $41.18 Million | -$72.18 Million | 64.36x | N/A |
| 2020 | $872.14 Million | $41.18 Million | $1.94 Million | 21.18x | 449.33x |
Competitor Companies of NERV by Market Capitalization
Companies near Minerva Neurosciences Inc in the global market cap rankings as of November 5, 2026. Also see how large is Minerva Neurosciences Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Minerva Neurosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Minerva Neurosciences Inc (2015–2026)
Market capitalization of Minerva Neurosciences Inc from 2015 to today. Between 2015 and today, Minerva Neurosciences Inc's market cap moved from $2.26 Billion to $ 109.48 Million, with a yearly change of -23.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $109.48 Million | -41.54% |
| 2025 | $187.29 Million | +80.95% |
| 2024 | $103.50 Million | -63.88% |
| 2023 | $286.52 Million | +286.79% |
| 2022 | $74.08 Million | -75.19% |
| 2021 | $298.54 Million | -65.77% |
| 2020 | $872.14 Million | -67.09% |
| 2019 | $2.65 Billion | +5.49% |
| 2018 | $2.51 Billion | +11.40% |
| 2017 | $2.25 Billion | -48.51% |
| 2016 | $4.38 Billion | +93.57% |
| 2015 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Minerva Neurosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $109.48 Million USD |
| MoneyControl | $109.48 Million USD |
| MarketWatch | $109.48 Million USD |
| marketcap.company | $109.48 Million USD |
| Reuters | $109.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more